Equities Analysts Set Expectations for EW FY2024 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Research analysts at Zacks Research boosted their FY2024 earnings estimates for shares of Edwards Lifesciences in a research report issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.58 per share for the year, up from their previous forecast of $2.57. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q4 2024 earnings at $0.55 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.72 EPS and FY2026 earnings at $2.76 EPS.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 EPS.

Several other brokerages have also recently issued reports on EW. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Jefferies Financial Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Robert W. Baird cut their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, The Goldman Sachs Group lifted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $79.40.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $74.16 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $43.74 billion, a price-to-earnings ratio of 10.70, a price-to-earnings-growth ratio of 3.61 and a beta of 1.12. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a 50-day simple moving average of $71.52 and a two-hundred day simple moving average of $72.31.

Insider Activity

In related news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,500 shares of company stock worth $2,508,350 in the last three months. Company insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently made changes to their positions in the company. Purus Wealth Management LLC boosted its holdings in Edwards Lifesciences by 5.2% during the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after purchasing an additional 160 shares during the last quarter. JFS Wealth Advisors LLC lifted its position in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares in the last quarter. Seascape Capital Management boosted its stake in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after buying an additional 174 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its holdings in shares of Edwards Lifesciences by 1.2% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock valued at $1,417,000 after acquiring an additional 184 shares in the last quarter. Finally, Martin Capital Advisors LLP increased its position in shares of Edwards Lifesciences by 0.7% during the third quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock valued at $1,686,000 after acquiring an additional 186 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.